Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and Immunology subsequent to the selection of two existing assets of PTX for the testing program for SARS-CoV-2 Antiviral Drugs Program of the Doherty Institute.
Notably, both assets were evaluated as Group 1 priority candidates.
Moreover, Prescient has filed new patent applications for the use of both assets as anti-SARS-CoV-2 agents and all additional IP generated during the screening by the Doherty Institute will be owned by PTX.
Post announcement on 21 July 2020, PTX quoted at A$0.069 climbed by 18.966% at AEST 11:37 AM.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.